AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Clinical and virological characteristics and retreatment of patients with chronic hepatitis C virus infection and failure to sofosbuvir, velapatasvir, and voxilaprevir in real-worldView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Molecular characterization in HCV late relapser patients treated with direct-acting antiviral (DAA) drugsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Resistant minority variants observed in failing patients at week 48 in ANRS 170 QUATUOR trial (a 4/7 days maintenance strategy vs a 7/7 days regimen in patients with controlled viral load)View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Virological efficacy and resistance evaluation in people living with HIV starting an STR regimenView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Variability in HIV Proviral DNA Genotyping Results from a Single Blood DrawView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Multicentric Castleman Disease HHV-8 related in a HIV patientView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020HIV Seronegativity After Rapid ART: A Case Demonstrating Future Challenges in HIV Confirmation Testing in the Era of iARTView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Assessment of quality of life among patients with hepatitis C in GeorgiaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Difficulty in reaching virological suppression in a long-term treated HIV-1 patient: rather the role of the reservoir than drug resistance?View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Integrase Resistance development after long-term suppressive treatment with Abacavir, Lamivudine and DolutegravirView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Case report: poor adherence to dolutegravir is associated with selection of resistance mutations T66I, G118R, E138A and L74IView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Comprehensive assessment of SARS-CoV-2 key genetic elements single or in clusters underlying geographically-dependent genetic evolutionary adaptation and their impact on drugs binding affinity and immune escapeView Abstract
